Trials / Completed
CompletedNCT01935453
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer
A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- OrienGene Biotechnology Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to study the safety of OrienX010 in the treatment of kinds of solid tumors such as melanoma,liver cancer,pancreatic cancer and lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recombinant hGM-CSF Herpes Simplex Virus Injection |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2014-05-01
- First posted
- 2013-09-05
- Last updated
- 2016-09-01
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01935453. Inclusion in this directory is not an endorsement.